28 July 2021

This Wednesday, 48 hours after receiving the first dose of Abdala, the adolescents between 12 and 18 years old participating in the phase II of the Ismaelillo study returned to the vaccinations. There they measured their temperature, their blood pressure and told how they felt after the immunization. So rigorous is the clinical trial that evaluates the safety and immunogenicity of this Cuban vaccine in the pediatric population.